1.Management of Anemia in Patients with Inflammatory Bowel Disease.
The Korean Journal of Gastroenterology 2015;65(3):145-150
Anemia is one of the commonest extraintestinal manifestations of inflammatory bowel disease (IBD). The pathogenesis of anemia in IBD is complex but iron deficiency combined with inflammation is the most common factor related to the development of anemia. However, other causes such as vitamin B12 and folate deficiency, hemolysis, myelosuppression and drug also should not be overlooked. In addition to ferritin, inflammatory markers and new biochemical parameters such as hepcidin and ferritin index are being tested as diagnostic a tool. First step for treatment is disease activity control and iron supplementation. Although oral iron is widely used, intravenous iron therapy should be considered in patients who are intolerant to oral iron therapy, have severe and refractory anemia or are in active disease state. Recently, new intravenous iron formulations have been introduced and due to their safety and easy usage, they have become the standard treatment modality for managing anemia in IBD. Erythropoietin and transfusion can be considered in specific situations. Vitamin B12 and folate supplementation is also important in patients who are deficient of these micronutrients. Since anemia in IBD patients could significantly influence the disease outcome, further studies and standard guideline for IBD are needed.
Anemia/*drug therapy/etiology
;
Biomarkers/analysis
;
Ferritins/analysis
;
Hepcidins/analysis
;
Humans
;
Inflammatory Bowel Diseases/complications/*diagnosis
;
Iron/*therapeutic use
;
Vitamin B 12/therapeutic use
2.Hepcidin-orchestrated Hemogram and Iron Homeostatic Patterns in Two Models of Subchronic Hepatic injury.
Ibtsam GHEITH ; Abubakr EL-MAHMOUDY
Biomedical and Environmental Sciences 2019;32(3):153-161
OBJECTIVE:
This study was designed to evaluate hematological disorders and the orchestrating roles of hepcidin and IL-6 in rat models of thioacetamide (TAA) and carbon tetrachloride (CCl4) hepatotoxicity.
METHODS:
Rats were intraperitoneally injected with TAA (10 mg/100 g rat weight dissolved in isosaline) or CCl4 (100 μL/100 g rat weight diluted as 1:4 in corn oil) twice weekly for eight consecutive weeks to induce subchronic liver fibrosis. Blood and tissue samples were collected and analyzed.
RESULTS:
CCl4 but not TAA significantly decreased the RBCs, Hb, PCV, and MCV values with minimal alterations in other erythrocytic indices. Both hepatotoxins showed leukocytosis, granulocytosis, and thrombocytopenia. By the end of the experiment, the erythropoietin level increased in the CCl4 model. The serum iron, UIBC, TIBC, transferrin saturation%, and serum transferrin concentration values significantly decreased, whereas that of ferritin increased in the CCl4 model. TAA increased the iron parameters toward iron overload. RT-PCR analysis revealed increased expression of hepatic hepcidin and IL-6 mRNAs in the CCl4 model and suppressed hepcidin expression without significant effect on IL-6 in the TAA model.
CONCLUSION
These data suggest differences driven by hepcidin and IL-6 expression between CCl4 and TAA liver fibrosis models and are of clinical importance for diagnosis and therapeutics of liver diseases.
Animals
;
Blood Chemical Analysis
;
Carbon Tetrachloride
;
toxicity
;
Hepcidins
;
pharmacology
;
Injections, Intraperitoneal
;
Interleukin-6
;
pharmacology
;
Iron
;
blood
;
metabolism
;
Leukocytosis
;
chemically induced
;
therapy
;
Liver Cirrhosis
;
chemically induced
;
therapy
;
Male
;
Rats
;
Thioacetamide
;
toxicity
;
Thrombocytopenia
;
chemically induced
;
therapy
;
Transferrin
;
metabolism